{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T23:39:45Z","timestamp":1720481985472},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T00:00:00Z","timestamp":1440028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bone.2015.08.016","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T22:46:28Z","timestamp":1440024388000},"page":"427-434","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effect of SI-591, a new class of cathepsin K inhibitor with peptidomimetic structure, on bone metabolism in vitro and in vivo"],"prefix":"10.1016","volume":"81","author":[{"given":"Toshiaki","family":"Fujii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9773","key":"10.1016\/j.bone.2015.08.016_bb0005","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bone.2015.08.016_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/tcrm.2006.2.3.281","article-title":"Management of age-related osteoporosis and prevention of associated fractures","volume":"2","author":"Maclaughlin","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"issue":"3","key":"10.1016\/j.bone.2015.08.016_bb0015","first-page":"193","article-title":"Diagnosis and treatment of osteoporosis","volume":"79","author":"Sweet","year":"2009","journal-title":"Am. Fam. Physician"},{"issue":"1","key":"10.1016\/j.bone.2015.08.016_bb0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","article-title":"Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability","volume":"49","author":"Bellido","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2015.08.016_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/rheumatology\/ket236","article-title":"Safety issues with bisphosphonate therapy for osteoporosis","volume":"53","author":"Suresh","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.bone.2015.08.016_bb0030","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","article-title":"Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis","volume":"28","author":"Gedmintas","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2015.08.016_bb0035","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/jbmr.5650071110","article-title":"Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women","volume":"7","author":"Hassager","year":"1992","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2015.08.016_bb0040","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/clinchem\/39.4.635","article-title":"Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation","volume":"39","author":"Risteli","year":"1993","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.bone.2015.08.016_bb0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2006.07.015","article-title":"A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys","volume":"40","author":"Kumar","year":"2007","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2015.08.016_bb0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.106.102798","article-title":"An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo -piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats","volume":"318","author":"Kim","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.bone.2015.08.016_bb0055","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1359\/jbmr.1999.14.10.1654","article-title":"Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization","volume":"14","author":"Gowen","year":"1999","journal-title":"J. Bone Miner. Res."},{"issue":"23","key":"10.1016\/j.bone.2015.08.016_bb0060","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","article-title":"Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice","volume":"95","author":"Saftig","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bone.2015.08.016_bb0065","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jemt.10374","article-title":"Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities","volume":"61","author":"Delaiss\u00e9","year":"2003","journal-title":"Microsc. Res. Tech."},{"issue":"2","key":"10.1016\/j.bone.2015.08.016_bb0070","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2310\/JIM.0b013e318202a9db","article-title":"Familial pycnodysostosis: identification of a novel mutation in the CTSK gene (cathepsin K)","volume":"59","author":"Toral-L\u00f3pez","year":"2011","journal-title":"J. Investig. Med."},{"issue":"5","key":"10.1016\/j.bone.2015.08.016_bb0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00198-006-0311-y","article-title":"High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K","volume":"18","author":"Schilling","year":"2007","journal-title":"Osteoporos. Int."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2015.08.016_bb0080","first-page":"S24","article-title":"Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia\/osteoporosis (abstract)","volume":"21","author":"Adami","year":"2006","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2015.08.016_bb0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaad.2008.03.009","article-title":"Drug-induced morphea: report of a case induced by balicatib and review of the literature","volume":"59","author":"Peroni","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.bone.2015.08.016_bb0090","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2010.11.033","article-title":"Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib","volume":"66","author":"R\u00fcnger","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"issue":"24","key":"10.1016\/j.bone.2015.08.016_bb0095","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1021\/jm0504961","article-title":"Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off target cathepsins and reduced functional selectivity","volume":"48","author":"Falgueyret","year":"2005","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bone.2015.08.016_bb0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/mol.107.039511","article-title":"Effect of cathepsin k inhibitor basicity on in vivo off-target activities","volume":"73","author":"Desmarais","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bone.2015.08.016_bb0105","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1074\/jbc.271.4.2126","article-title":"Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme","volume":"271","author":"Br\u00f6mme","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bone.2015.08.016_bb0110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/bj2450381","article-title":"Enzyme-substrate interactions in the hydrolysis of peptides by cathepsin B and H from rat liver","volume":"245","author":"Br\u00f6mme","year":"1987","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.bone.2015.08.016_bb0115","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0006-291X(88)80356-5","article-title":"Cathepsin L a latent proteinase in guinea pig sperm","volume":"151","author":"McDonald","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bone.2015.08.016_bb0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1042\/bj2640467","article-title":"from bovine spleen. Purification, distribution, intracellular localization and action on proteins","volume":"264","author":"Kirshke","year":"1989","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.bone.2015.08.016_bb0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1479-5876-2-6","article-title":"Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay","volume":"2","author":"Susa","year":"2004","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.bone.2015.08.016_bb0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S8756-3282(99)00197-0","article-title":"Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment","volume":"25","author":"Ito","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.08.016_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bone.2015.08.016_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jb\/mvn093","article-title":"Species differences between human and rat in the substrate specificity of cathepsin K","volume":"144","author":"Tada","year":"2008","journal-title":"J. Biochem."},{"issue":"1A","key":"10.1016\/j.bone.2015.08.016_bb0145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0300-9629(74)90554-4","article-title":"Effect of low calcium diet on bone and calcium metabolism in rats and mice\u2014a differential species response","volume":"49","author":"Wolinsky","year":"1974","journal-title":"Comp. Biochem. Physiol. A Comp. Physiol."},{"issue":"1","key":"10.1016\/j.bone.2015.08.016_bb0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02059044","article-title":"Structure of long bones of rats and mice fed a low calcium diet","volume":"15","author":"Ornoy","year":"1974","journal-title":"Calcif. Tissue Res."},{"issue":"1","key":"10.1016\/j.bone.2015.08.016_bb0155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.22203\/eCM.v001a08","article-title":"Animal models of osteoporosis\u2014necessity and limitations","volume":"22","author":"Turner","year":"2001","journal-title":"Eur. Cell. Mater."},{"issue":"8 Pt 2","key":"10.1016\/j.bone.2015.08.016_bb0160","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/clinchem\/45.8.1347","article-title":"Hormonal control of calcium homeostasis","volume":"45","author":"Mundy","year":"1999","journal-title":"Clin. Chem."},{"issue":"4 Suppl.","key":"10.1016\/j.bone.2015.08.016_bb0165","doi-asserted-by":"crossref","first-page":"125S","DOI":"10.1016\/8756-3282(95)00285-L","article-title":"FDA Guidelines and animal models for osteoporosis","volume":"17","author":"Thompson","year":"1995","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2015.08.016_bb0170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1359\/jbmr.2001.16.3.541","article-title":"Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats","volume":"16","author":"Tamura","year":"2001","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2015.08.016_bb0175","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1359\/jbmr.81005","article-title":"Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats","volume":"24","author":"Cheng","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2015.08.016_bb0180","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1359\/jbmr.071207","article-title":"Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat","volume":"23","author":"Gasser","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"1-2","key":"10.1016\/j.bone.2015.08.016_bb0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0009-8981(01)00656-8","article-title":"Biochemical markers of bone turnover","volume":"313","author":"Swaminathan","year":"2001","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"10.1016\/j.bone.2015.08.016_bb0190","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","article-title":"A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density","volume":"40","author":"Saag","year":"2007","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2015.08.016_bb0195","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2015.08.016_bb0200","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"Goh","year":"2007","journal-title":"J. Bone Joint Surg. (Br.)"},{"issue":"6","key":"10.1016\/j.bone.2015.08.016_bb0205","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1359\/jbmr.081253","article-title":"Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia","volume":"24","author":"Whyte","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2015.08.016_bb0210","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2015.08.016_bb0215","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9810","key":"10.1016\/j.bone.2015.08.016_bb0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bone.2015.08.016_bb0225","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","article-title":"Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN","volume":"90","author":"Barasch","year":"2011","journal-title":"J. Dent. Res."},{"issue":"3","key":"10.1016\/j.bone.2015.08.016_bb0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J. Oral Maxillofac. Surg."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328215003270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328215003270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T06:22:47Z","timestamp":1599459767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328215003270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":46,"alternative-id":["S8756328215003270"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2015.08.016","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of SI-591, a new class of cathepsin K inhibitor with peptidomimetic structure, on bone metabolism in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2015.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}